Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Italian Translation
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goetz, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goetz, C. G.
Related Collections
Right arrow Parkinson's disease/Parkinsonism
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2006;66:1427-1429
© 2006 American Academy of Neurology
Brief Communications

Safety of rasagiline in elderly patients with Parkinson disease

C. G. Goetz, MD, S. R. Schwid, MD, S. W. Eberly, MS, D. Oakes, PhD, I. Shoulson, MD and the Parkinson Study Group TEMPO and PRESTO Investigators*

From Rush University Medical Center (C.G.G.), Chicago, IL; and University of Rochester (S.R.S., S.W.E., D.O., I.S.), Rochester, NY.

Address correspondence and reprint requests to Dr. Christopher G. Goetz, Rush University Medical Center, Suite 755, 1725 West Harrison Street, Chicago, IL 60612; e-mail: cgoetz{at}rush.edu

The authors examined age effects on adverse events from two randomized, controlled trials of rasagiline, comparing younger (younger than70 years) and older (70 years and older) subjects. Older patients were more prone to serious adverse effects than younger patients, but there was no statistical interaction between age and rasagiline exposure. This absence of an age-rasagiline interaction suggests that rasagiline does not require special safety precautions for elderly subjects with Parkinson disease.

*The Parkinson Study Group investigators are listed in the appendix.

Disclosure: TEMPO and PRESTO studies were supported in the United States by Teva Neuroscience, Inc., in partnership with Eisai, Inc., and by TEVA Pharmaceutical Industries Ltd. and Lundbeck A/S. No additional funding was provided for the data analysis pertinent to this report.

Received July 12, 2005. Accepted in final form January 26, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.